#152781

Anti-BAG3 [V65P1E8*D2]

Cat. #152781

Anti-BAG3 [V65P1E8*D2]

Cat. #: 152781

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: BAG family molecular chaperone regulator 3

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-BAG3 [V65P1E8*D2]
  • Alternate name: BAG3, Bcl-2-associated athanogene 3, Bcl-2-binding protein Bis, Docking protein CAIR-1
  • Clone: V65P1E8*D2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: Anti-BCL2-Associated Athanogene 3 (BAG3) [V65P1E8*D2] is specific for human BAG3. BAG3 is involved in chaperone-assisted selective autophagy. Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. In muscle cells, BAG3 cooperates with the molecular chaperones Hsc70 and HspB8 to induce the degradation of mechanically damaged cytoskeleton components in lysosomes. This process is called chaperone-assisted selective autophagy (CASA) and is essential for maintaining muscle activity. Defects in BAG3 are the cause of myopathy myofibrillar BAG3-related (MFM-BAG3) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients.
  • Immunogen: Ovalbumin-conjugated synthetic peptide MTDTPGNPAAP
  • Isotype: IgG1 kappa
  • Myeloma used: P3X63Ag8.653

Target Details

  • Target: BAG family molecular chaperone regulator 3
  • Target background: Anti-BCL2-Associated Athanogene 3 (BAG3) [V65P1E8*D2] is specific for human BAG3. BAG3 is involved in chaperone-assisted selective autophagy. Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. In muscle cells, BAG3 cooperates with the molecular chaperones Hsc70 and HspB8 to induce the degradation of mechanically damaged cytoskeleton components in lysosomes. This process is called chaperone-assisted selective autophagy (CASA) and is essential for maintaining muscle activity. Defects in BAG3 are the cause of myopathy myofibrillar BAG3-related (MFM-BAG3) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C